Table 2. Final response to pegIFNα2a+RBV or DAA treatments.
| pegIFNα2a+RBV treatment of 261 Mexican patients with CHC and viral genotype 1 | ||||||
|---|---|---|---|---|---|---|
| Final response | Subtypes of Genotype 1 | |||||
| 1 + 1a1b* | 1a | 1b | Total | |||
| NR, n (%) | 18 (6.9) | 69 (26.4) | 80 (30.7) | 167 (64) | ||
| SVR, n (%) | 12 (4.6) | 41 (15.7) | 41 (15.7) | 94 (36) | ||
| Total | 30 (11.5) | 110 (42.1) | 121 (46.4) | 261 (100) | ||
| DAA treatments in 83 previously treated Mexican patients with CHC and viral genotype 1 | ||||||
| Regimen | SVR12, n (%) | NR12, n (%) | Total | |||
| OBV/PTV/r/DSV+RBV | 7 (87.5) | 1 (12.5) | 8 (100) | |||
| OBV/PTV/r/DSV | 30 (96.8) | 1 (3.2) | 31 (100) | |||
| Total | 37 (94.8) | 2 (5.2) | 39 (100) | |||
| SOF/LDV+RBV | 34 (100.0) | 0 (0.0) | 34 (100.0) | |||
| SOF/LDV | 10 (100) | 0 (0.0) | 10 (100) | |||
| Total | 44 (100) | 0 (0.0) | 44 (100) | |||
Notes.
- NR
- Non-responder
- SVR
- sustained virological response
- p
- value for Fisher’s Exact test
Statistical significance was defined as p < 0.05 (final response among genotypes).
*
Includes patients with unsubtyped HCV genotype 1 (n = 10) and those detected as 1a1b (n = 20).
SVR12, sustained virological response for DAA treatments; NR12, Non-responder for DAA treatments.